Understanding how a new vitamin D derivative affects skin health
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin
This study is looking at a new form of vitamin D called 20(OH)D3 to see how it can help improve skin health and fight skin issues like inflammation and cancer, so people with skin conditions might find new ways to feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11052961 on NIH RePORTER |
What this research studies
This research investigates the effects of a novel secosteroid, 20(OH)D3, on skin health and its potential mechanisms of action. The study explores how this compound, which is produced from vitamin D3, can regulate skin barrier functions and exhibit anti-inflammatory and anti-cancer properties. By examining both in vitro and in vivo models, the research aims to uncover the biological activities of 20(OH)D3 and its metabolites, which may offer new therapeutic options for skin-related conditions. Patients may benefit from insights into how this compound can improve skin health and combat skin diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with skin conditions that may benefit from anti-inflammatory or anti-cancer treatments.
Not a fit: Patients with skin conditions unrelated to inflammation or cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for skin conditions and improved skin health through the use of 20(OH)D3.
How similar studies have performed: Other research has shown promising results with vitamin D derivatives in skin health, suggesting that this approach may be effective.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Slominski, Andrzej T — University of Alabama at Birmingham
- Study coordinator: Slominski, Andrzej T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.